The Meningitis drugs in development market research report provides comprehensive information on the therapeutics under development for Meningitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Meningitis. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Meningitis and features dormant and discontinued products.

GlobalData tracks 27 drugs in development for Meningitis by 21 companies/universities/institutes. The top development phase for Meningitis is phase iii with eight drugs in that stage. The Meningitis pipeline has 21 drugs in development by companies and six by universities/ institutes. Some of the companies in the Meningitis pipeline products market are: Chongqing Zhifei Biological Products, CanSino Biologics and Institute of Medical Biology Chinese Academy of Medical Sciences.

The key targets in the Meningitis pipeline products market include GPI Anchored Wall Transfer Protein 1 (PfGWT1 or EC 2.3.), Thymidylate Synthase (TYMS or EC 2.1.1.45), and Meningococcal Capsular Polysaccharide Antigen.

The key mechanisms of action in the Meningitis pipeline product include GPI Anchored Wall Transfer Protein 1 (PfGWT1 or EC 2.3.) Inhibitor with two drugs in Preclinical. The Meningitis pipeline products include four routes of administration with the top ROA being Intramuscular and six key molecule types in the Meningitis pipeline products market including Conjugate Vaccine, and Small Molecule.

Meningitis overview

Meningitis is the inflammation of the meninges, protective membranes covering the brain and spinal cord. The cause of inflammation can be infection by viruses, bacteria, or other microorganisms, and less commonly by certain drugs. As the inflammation is in proximity to the brain and spinal cord, meningitis can be life-threatening, depending on its cause. Viral meningitis is not life-threatening; those affected can be recover quickly. Bacterial meningitis is serious and life-threatening. The three major bacteria are Neisseria meningitides, which causes meningococcal meningitis; pneumococcal meningitis is caused by the bacteria streptococcus pneumonia; and haemophilius influenza causes meningitis in infants. 44–46% of cases of bacterial meningitis have all of the following three symptoms: severe headache, nuchal ridgidity (inability to flex the neck forward), and altered mental status. Severe headache occurs in 90% of the cases. Other symptoms include photophobia (fear of bright light) and phonophobia (fear of loud noises). In infants up to 6 months, bulging of the fontanelle (soft spot on the baby’s head) may be visible. Less severe symptoms, including extreme cold, abnormality in skin color, and leg pain, may also be distinguishing features for meningitis.

For a complete picture of Meningitis’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.